EXACT Therapeutics AS Logo

EXACT Therapeutics AS

Biopharma firm using ultrasound to enhance drug delivery for oncology via its ACT® platform.

EXTX | OL

Overview

Corporate Details

ISIN(s):
NO0010852205 (+1 more)
LEI:
2138006ZE5JAL39AGD55
Country:
Norway
Address:
Østre Aker vei 19, 0581 Oslo

Description

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing a technology platform for targeted therapeutic enhancement called Acoustic Cluster Therapy (ACT®). The company's vision is to become a leading precision medicine company by utilizing ultrasound to improve drug delivery in oncology. The proprietary ACT® platform uses a biomechanical mode of action to increase the uptake of co-administered drugs from blood vessels into the surrounding cancer tissue without damaging capillary walls. This technology is designed to be compatible with existing hospital ultrasound systems, requires no drug reformulation, and has shown potential in targeting tumors and crossing the blood-brain barrier. A key focus area is pancreatic cancer, with a clinical program in Phase 2 trials.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-25 12:57
EXACT Therapeutics to present company update - Attachment: 251125 Exact Therap…
English 1.5 MB
2025-11-25 12:57
EXACT Therapeutics to present company update
English 1.1 KB
2025-11-24 08:25
EXACT Therapeutics AS: New option program and receipt of share options by prima…
English 112.5 KB
2025-11-24 08:25
EXACT Therapeutics AS: New option program and receipt of share options by prima…
English 2.2 KB
2025-09-25 08:00
EXACT Therapeutics first half 2025 interim results - Attachment: EXACT Therape…
English 743.7 KB
2025-09-25 08:00
EXACT Therapeutics first half 2025 interim results
English 1.4 KB
2025-09-18 08:00
EXACT Therapeutics’ Phase 2 trial to be presented at the 2025 AACR Special Conf…
English 2.0 KB
2025-09-09 08:00
EXACT Therapeutic’s Acoustic Cluster Therapy to be presented at the Ninth Inter…
English 2.0 KB
2025-08-12 08:30
EXACT Therapeutics to Present at the European Society for Medical Oncology (ESM…
English 1.8 KB
2025-08-11 11:08
Financial calendar
English 430 bytes
2025-07-08 08:30
EXACT Therapeutics announces grant of core patent in the U.S.
English 1.9 KB
2025-06-24 08:00
EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients w…
English 3.0 KB
2025-06-13 12:09
EXACT Therapeutics AS: Primary insider notification - Attachment: Notification …
English 41.4 KB
2025-06-13 12:09
EXACT Therapeutics AS: Primary insider notification
English 1.3 KB
2025-06-13 12:05
EXACT Therapeutics minutes from Annual General Meeting June 13, 2025 - Attachme…
Norwegian 729.7 KB

Automate Your Workflow. Get a real-time feed of all EXACT Therapeutics AS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EXACT Therapeutics AS

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EXACT Therapeutics AS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.